• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

摩洛哥多发性硬化症:流行病学、临床和治疗特征。

Multiple sclerosis in Morocco: Epidemiological, clinical, and therapeutic profile.

机构信息

Biological Engineering Laboratory, Faculty of Sciences and Techniques, Sultan Moulay Slimane University, Beni Mellal, Morocco.

Biological Engineering Laboratory, Faculty of Sciences and Techniques, Sultan Moulay Slimane University, Beni Mellal, Morocco.

出版信息

Mult Scler Relat Disord. 2024 Jan;81:105347. doi: 10.1016/j.msard.2023.105347. Epub 2023 Dec 2.

DOI:10.1016/j.msard.2023.105347
PMID:38061315
Abstract

OBJECTIVE

This study aims to describe the clinical, therapeutic, and epidemiological profiles of MS patients in Morocco.

METHODS

This descriptive study involved 170 patients representing four Morocco regions. We collected the data using an electronic survey.

RESULTS

The results show female dominance in patients with MS. Besides, most patients present with relapsing-remitting MS (RRMS). The main clinical symptoms reported by patients are fatigue, cognitive issues, spasticity, bowel or bladder complaints, and visual issues. Furthermore, the findings show that almost half of the patients use Interferon bêta-1a and azathioprine as disease-modifying therapies; 60.5 % use traditional and complementary medicine, of which 30.6 % use cupping, 30 % recite the Holy Quran, and 28.2 % use apitherapy. The findings show that there is a statistically significant relationship between specific MS factors such as professional activity (p = 0.0071), degree of satisfaction with treatment (p = 0.005), stress (p = 0.014), and the frequency of relapses.

CONCLUSIONS

In addition to DMT, patients also use traditional and complementary medicine. There is also a relationship between some epidemiological characteristics and the frequency of relapses in patients with MS.

摘要

目的

本研究旨在描述摩洛哥多发性硬化症(MS)患者的临床、治疗和流行病学特征。

方法

本描述性研究纳入了来自摩洛哥四个地区的 170 名患者。我们通过电子调查收集数据。

结果

结果显示,MS 患者以女性为主。此外,大多数患者表现为复发缓解型 MS(RRMS)。患者报告的主要临床症状包括疲劳、认知问题、痉挛、肠或膀胱问题以及视力问题。此外,研究结果表明,近一半的患者使用干扰素β-1a 和硫唑嘌呤作为疾病修正治疗;60.5%的患者使用传统和补充医学,其中 30.6%使用拔罐,30%诵读《古兰经》,28.2%使用蜂疗。研究结果表明,MS 患者的一些特定因素(如职业活动、治疗满意度、压力和复发频率)与特定因素之间存在统计学显著关系。

结论

除了 DMT,患者还使用传统和补充医学。MS 患者的一些流行病学特征与复发频率之间也存在关系。

相似文献

1
Multiple sclerosis in Morocco: Epidemiological, clinical, and therapeutic profile.摩洛哥多发性硬化症:流行病学、临床和治疗特征。
Mult Scler Relat Disord. 2024 Jan;81:105347. doi: 10.1016/j.msard.2023.105347. Epub 2023 Dec 2.
2
Real-world disease-modifying therapy usage in persons with relapsing-remitting multiple sclerosis: Cross-sectional data from the Swiss Multiple Sclerosis Registry.复发缓解型多发性硬化症患者的真实世界疾病修正疗法使用情况:来自瑞士多发性硬化症登记处的横断面数据。
Mult Scler Relat Disord. 2022 Apr;60:103706. doi: 10.1016/j.msard.2022.103706. Epub 2022 Feb 21.
3
Real-world propensity score comparison of treatment effectiveness of peginterferon beta-1a vs. subcutaneous interferon beta-1a, glatiramer acetate, and teriflunomide in patients with relapsing-remitting multiple sclerosis.真实世界中聚乙二醇干扰素 β-1a 与皮下干扰素 β-1a、那他珠单抗和特立氟胺治疗复发缓解型多发性硬化症患者的疗效的倾向评分比较。
Mult Scler Relat Disord. 2021 Jun;51:102935. doi: 10.1016/j.msard.2021.102935. Epub 2021 Apr 8.
4
Current and future trends in multiple sclerosis management: Near East perspective.多发性硬化症管理的现状和未来趋势:近东视角。
Mult Scler Relat Disord. 2023 Aug;76:104800. doi: 10.1016/j.msard.2023.104800. Epub 2023 Jun 5.
5
Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis.用于多发性硬化症的免疫调节剂和免疫抑制剂:一项网状Meta分析
Cochrane Database Syst Rev. 2013 Jun 6;2013(6):CD008933. doi: 10.1002/14651858.CD008933.pub2.
6
Factors influencing patients' willingness-to-pay for disease-modifying therapies for multiple sclerosis.影响患者对多发性硬化症疾病修正疗法支付意愿的因素。
Mult Scler Relat Disord. 2021 Feb;48:102720. doi: 10.1016/j.msard.2020.102720. Epub 2020 Dec 24.
7
Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis.干扰素β与醋酸格拉替雷治疗复发缓解型多发性硬化症的对比
Cochrane Database Syst Rev. 2016 Nov 24;11(11):CD009333. doi: 10.1002/14651858.CD009333.pub3.
8
Cost-effectiveness analysis of peginterferon beta-1a compared with interferon beta-1a and glatiramer acetate in the treatment of relapsing-remitting multiple sclerosis in the United States.在美国,用聚乙二醇干扰素β-1a 与干扰素β-1a 和那他珠单抗治疗复发缓解型多发性硬化的成本效果分析。
J Med Econ. 2016 Jul;19(7):684-95. doi: 10.3111/13696998.2016.1157080. Epub 2016 Mar 7.
9
[Long-term treatment for multiple sclerosis with interferon beta-1b. Outcomes of an open, retrospective, observational study].[干扰素β-1b对多发性硬化症的长期治疗。一项开放性回顾性观察研究的结果]
Zh Nevrol Psikhiatr Im S S Korsakova. 2022;122(7. Vyp. 2):96-103. doi: 10.17116/jnevro202212207296.
10
[Efficacy and safety of sampeginterferon β-1a in the treatment of relapsing remitting multiple sclerosis: results of 52 weeks of therapy in a randomized, double-blind clinical trial].司美peg干扰素β-1a治疗复发缓解型多发性硬化症的疗效与安全性:一项随机双盲临床试验52周治疗结果
Zh Nevrol Psikhiatr Im S S Korsakova. 2022;122(1):62-71. doi: 10.17116/jnevro202212201162.

引用本文的文献

1
HLA-DRB1 and DQB1 Allelic Polymorphism and Multiple Sclerosis in a Moroccan Population.摩洛哥人群中 HLA - DRB1 和 DQB1 等位基因多态性与多发性硬化症
Curr Issues Mol Biol. 2025 Jun 13;47(6):458. doi: 10.3390/cimb47060458.
2
Enhancing quality of life in multiple sclerosis: A study protocol to evaluate the impact of a therapeutic education program.提高多发性硬化症患者的生活质量:一项评估治疗性教育项目影响的研究方案。
J Educ Health Promot. 2025 Feb 28;14:49. doi: 10.4103/jehp.jehp_1351_24. eCollection 2025.
3
The impact of fatigue on people with multiple sclerosis in Morocco.
疲劳对摩洛哥多发性硬化症患者的影响。
Afr J Disabil. 2024 Jul 31;13:1376. doi: 10.4102/ajod.v13i0.1376. eCollection 2024.